
Safety of medicinal products
Safety of medicinal products
AIFA monitors the safe use of medicinal products to ensure the benefit/risk profile of each medicine is positive. Such activity is carried out through the continuous monitoring and evualuation of safety information and, where necessary, through the adoption of regulatory actions in order to promptly protect public health.
AIFA also ensures independent and timely information on the safety of medicinal products by encouraging patients and healthcare professionals to report suspected adverse reactions.
In addition, it promotes active pharmacovigilance programs and studies, in agreement with Regions and according to training and research plans with general practicioners, free choice pediatrician, scientific societies and universities.
News on safety
12/01/2021
18/12/2020
15/12/2020
09/12/2020
01/12/2020
01/12/2020
Uffici di riferimento
Site Map
Safety of medicinal products
- Pharmacovigilance
- National Pharmacovigilance Network
- The RAM System
- Persons in charge of Pharmacovigilance
- European Eudravigilance System
- Adverse Reactions to medicinal products
- Regional pharmacovigilance funds
- Pharmacovigilance signals
- PSURs (Periodic safety update reports)
- Risk management measures
- Medicinal products subject to additional monitoring
Nested Applications
Nested Applications
Last tweets
Go to Twitter profile
Multimedia